| pubmed-article:1443485 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1443485 | lifeskim:mentions | umls-concept:C0023911 | lld:lifeskim |
| pubmed-article:1443485 | lifeskim:mentions | umls-concept:C0016293 | lld:lifeskim |
| pubmed-article:1443485 | lifeskim:mentions | umls-concept:C0683150 | lld:lifeskim |
| pubmed-article:1443485 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:1443485 | pubmed:dateCreated | 1992-12-22 | lld:pubmed |
| pubmed-article:1443485 | pubmed:abstractText | Six patients were given flumazenil (1 mg) during the anhepatic period of liver transplantation. We found higher mean plasma flumazenil concentrations during the anhepatic period than occurred in patients with hepatic cirrhosis. It was only possible to measure plasma flumazenil concentrations in four patients after revascularisation of the donor liver. Of these, elimination half-lives could be calculated in only three patients (normal in one and prolonged in two). In these two patients the elimination half-lives were prolonged to the same extent as in patients with fulminant hepatic failure. The changes during the anhepatic period occur because the liver contributes to the central volume of distribution. After revascularisation of the donor organ the prolonged half-lives indicate that transplanted livers may not recover normal metabolic functions immediately. | lld:pubmed |
| pubmed-article:1443485 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1443485 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1443485 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:1443485 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1443485 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1443485 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:1443485 | pubmed:issn | 0003-2409 | lld:pubmed |
| pubmed-article:1443485 | pubmed:author | pubmed-author:ParkG RGR | lld:pubmed |
| pubmed-article:1443485 | pubmed:author | pubmed-author:PodkowikB IBI | lld:pubmed |
| pubmed-article:1443485 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1443485 | pubmed:volume | 47 | lld:pubmed |
| pubmed-article:1443485 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1443485 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1443485 | pubmed:pagination | 887-9 | lld:pubmed |
| pubmed-article:1443485 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:1443485 | pubmed:meshHeading | pubmed-meshheading:1443485-... | lld:pubmed |
| pubmed-article:1443485 | pubmed:meshHeading | pubmed-meshheading:1443485-... | lld:pubmed |
| pubmed-article:1443485 | pubmed:meshHeading | pubmed-meshheading:1443485-... | lld:pubmed |
| pubmed-article:1443485 | pubmed:meshHeading | pubmed-meshheading:1443485-... | lld:pubmed |
| pubmed-article:1443485 | pubmed:meshHeading | pubmed-meshheading:1443485-... | lld:pubmed |
| pubmed-article:1443485 | pubmed:meshHeading | pubmed-meshheading:1443485-... | lld:pubmed |
| pubmed-article:1443485 | pubmed:meshHeading | pubmed-meshheading:1443485-... | lld:pubmed |
| pubmed-article:1443485 | pubmed:meshHeading | pubmed-meshheading:1443485-... | lld:pubmed |
| pubmed-article:1443485 | pubmed:meshHeading | pubmed-meshheading:1443485-... | lld:pubmed |
| pubmed-article:1443485 | pubmed:year | 1992 | lld:pubmed |
| pubmed-article:1443485 | pubmed:articleTitle | Plasma concentrations of flumazenil during liver transplantation. | lld:pubmed |
| pubmed-article:1443485 | pubmed:affiliation | John Farman Intensive Care Unit, Addenbrooke's Hospital, Cambridge, UK. | lld:pubmed |
| pubmed-article:1443485 | pubmed:publicationType | Journal Article | lld:pubmed |
